Clinical Trial Update: Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial comparing combined apatinib mesylate and vinorelbine versus vinorelbine alone in triple-negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib Mesylate (apatinib)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Liaoning Cancer Hospital & Institute | Conditions: Triple-negative Breast Cancer | Phase 2 | Status: UNKNOWN